A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN 74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC).
- Roberts, Stuart (Primary Chief Investigator (PCI))
- Adams, Leon A. (Chief Investigator (CI))
- George, Jacob (Chief Investigator (CI))
- Strasser, Simone Irene (Chief Investigator (CI))
- Thompson, Alexander J.V. (Chief Investigator (CI))
- Lynch, Kate (Chief Investigator (CI))
Project: Research